February 05, 2026 05:26 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘We never said no’: Suryakumar Yadav says India ready for Pakistan clash at T20 World Cup | Supreme Court orders Mamata govt to clear pending dues | ‘India is free to buy oil from anyone’: Russia fires back at Trump’s crude deal claim | ‘Justice crying behind closed doors’: Mamata Banerjee slams ECI in Supreme Court, CJI Kant assures solution | Mummy, Papa, sorry: Three sisters jump to death after parents object to online gaming | Supreme Court raps Meta, WhatsApp: ‘Theft of private information, won’t allow its use’ | ‘Completely surrendered’: Congress slams Modi after Trump’s trade deal move | PM Modi thanks 'dear friend' Trump for tariff reduction, hails strong US–India partnership | Trump announces US–India trade deal, lowers reciprocal tariffs to 18% | After Budget mayhem, bulls return: Sensex, Nifty stage sharp recovery
Image: Youtube Screen grab

Saridon, Corex and 326 other combination drugs banned

| @indiablooms | Sep 13, 2018, at 06:47 pm

New Delhi, Sept 13 (IBNS) : The Ministry of Health has banned the production, sale of about 328 fixed dose combinations of drugs (FDCs), including Saridon and Corex, two popular drugs in the country, reports said.

This ban will bring an end to a long legal battle between the ministry and the drug manufacturers. The battle, which has been ongoing since 2016, called for these ‘unsafe’ drugs to be banned.

Around 6,000 drug brands are expected to be affected by this ban, among them popular brands such as Saridon (painkiller), Panderm (skin cream), Lupidiclox (antibiotic), Corex (cough syrup) and several others.

In December 2017, the Supreme Court asked Drugs Technical Advisory Board (DTAB) to intervene in the matter. The DTAB eventually said there was no therapeutic evidence that the ingredients in about 328 of these FDCs cause any harm to people.

The All India Drug Action Network sought the banning of the drugs which were not part of the DTAB report, as these itself accounted for about Rs 2,500 crore of the pharmaceutical market.

 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.